Background. Several studies have investigated associations between the -174G C single nucleotide polymorphism (rs1800795) of the IL6 gene and phenotypes related to type 2 diabetes mellitus (T2DM) but presented inconsistent results.
Introduction
Type 2 diabetes mellitus (T2DM) is a public health problem of pandemic proportions. Conservative estimates indicate that there are 171 million people in the world with symptomatic or asymptomatic diabetes mellitus and that this global prevalence will double by 2030 to 366 million people (1) . The spread of the disease is also alarming in Europe, even though Caucasians have a low to moderate prevalence of T2DM compared with most other ethnic groups worldwide (2) .
Type 2 diabetes mellitus is a multifactorial disease. While a lot is known about environmental risk factors for T2DM, identification of the genetic etiology of T2DM has proven to be challenging (3) . An interesting candidate variant for T2DM is the -174G C polymorphism (rs1800795) of the IL6 gene that codes for the cytokine interleukin-6 (IL-6). Interleukin-6 exerts pleiotropic biological functions in the regulation of the acute-phase reaction and immune responses, and is associated with T2DM and related diseases (4Á7). The promoter polymorphism IL6 -174G C, which has been shown to affect IL6 promoter activity (8, 9) , was reported to be associated with circulating IL-6 levels (8,10Á14), T2DM (15) , insulin resistance (16) , obesity (17Á 20), coronary heart disease (CHD) (21) , cholesterol levels (6) , and metabolic syndrome (22) . However, association estimates pointed in inconclusive directions, while other studies of these traits did not find any association.
At the start of our project, meta-analyses on association between IL6 -174G C and two different outcomes had been reported: 1) Sie et al. did not find statistically significant evidence for an association with CHD in 19,798 individuals (23) . Having large heterogeneity between association estimates, Qi et al. did not detect a statistically significant association with T2DM in 17,452 individuals of mainly published studies (24) . We established an international IL6-T2DM consortium on individual-level published and unpublished data and showed an almost 9% reduced T2DM risk for C-allele carriers in 20,976 individuals (25) . However, it was not clear yet whether the IL6 -174G C polymorphism impacts IL-6 levels which together with the T2DM association would support a causal role of IL-6 levels in T2DM. Moreover, studies on genetic association with obesity pointed in a direction that was opposite to the T2DM association (17, 18) . Finally, analyzing the dichotomous trait T2DM is a substantial restriction of information, which can be overcome by analyzing the quantitative trait circulating plasma or serum glucose in the fasting state or after an oral
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Ann Med Downloaded from informahealthcare.com by University of Michigan Health System glucose load. This is of special importance because the T2DM finding was borderline statistically significant (P 00.037) (25) , and a consistent glucose association would greatly underscore this finding. The objective of the present study was to clarify the epidemiological evidence for the association of IL6 -174G C polymorphism with circulating glucose levels, body mass index (BMI), and IL-6 levels as intermediate phenotypes on the way to T2DM. We used by far the largest individual-level data set on this polymorphism in relation to quantitative phenotypes to date. It is important to note that earlier studies detected associations between -174G C and IL-6 levels or obesity mostly in the presence of an inflammatory stimulus (10, 11) or in subjects having a chronic subclinical (19) , or an acute (12, 14) inflammatory state. The inclusion of T2DM studies in our joint analysis was essential to investigate whether the impact of IL6 -174G C indeed differed by the subclinical inflammatory state observed in type 2 diabetic individuals, as opposed to healthy subjects.
Subjects and methods
All studies of the IL6-T2DM consortium on Caucasian subjects with available BMI were included in this joint analysis of quantitative traits. Information on the inclusion criteria, the search strategy and recruitment of the studies, data cleaning, and genotyping methods is provided in the online appendix.
Definition of analyzed samples and data collection
Because the majority of included studies were crosssectional population-based or T2DM case-control studies, our main analysis focused on a combined sample of non-diabetic and prevalent T2DM subjects. We included the baseline examination of the two longitudinal cohort studies excluding subjects that developed T2DM during follow-up for this main analysis. All analyses were confined to Caucasian adults who were at least 18 years old with data on the genotype of the IL6 -174G C polymorphism, age, sex, BMI, and T2DM status. When known, type 1 diabetic individuals were excluded. In family studies, only the sibling generation was used. Data on circulating fasting and 2-hour plasma or serum glucose (measured two hours after consumption of 75 g glucose) and plasma or serum IL-6 levels were collected where available.
All participating studies have been conducted according to the principles expressed in the Declaration of Helsinki. Individual studies had either written informed consent for all subjects for genetic analyses or approval from their institutional review committee for genetic analyses. Further details on design of individual studies and use in this joint analysis are presented in the online appendix Table A-II.
Statistical analyses
Study-specific b-coefficients for the association between IL6 -174G C and the quantitative traits were estimated by linear regression, using SAS PROC GLM for studies with unrelated individuals and SAS PROC MIXED for family studies. All analyses were adjusted for age and sex. Primary analyses were performed including all subjects (full data analyses) additionally adjusting for T2DM status when analyzing BMI or IL-6 levels. Secondary analyses were conducted separately for the nondiabetic and the prevalent T2DM subjects (T2DM status-specific analyses), additionally adjusting for BMI when analyzing fasting, 2-hour glucose, or IL-6 levels. If a study featured less than 50 participants for a specific analysis, this study was not included in the joint analysis. Studies with fasting glucose only on either T2DM cases or controls (EDSC, EPICPOTSDAM_nCC-T2DM, and MONICA-S3) were excluded from the full data glucose analysis to assure a full range of glucose levels.
IL6 -174G C genotypes were analyzed modelfree, comparing CC-or GC-genotype with the wildtype GG, and additionally by applying a dominant genetic model for the C-allele, which was the model reported previously for the T2DM association (25) . Heterogeneity between study-specific b-coefficients was tested by the chi-square-based Q-statistic, and its impact was quantified by I 2 (26) . As the heterogeneity between study-specific b-coefficients was non-significant in all analyses (P0.10), the bcoefficients were combined using the inverse-variance fixed-effect model (27) . As recommended, summary association estimates of all studies with the genotype frequencies of non-diabetic subjects being in Hardy-Weinberg equilibrium (HWE) were reported as main results (28) .
A conservative Bonferroni-corrected significance level of 0.017 ( 00.05/3) was applied to account for the testing of the three phenotypes (glucose, BMI, and IL-6) in the primary (full data) analyses. Note that the phenotypes fasting and 2-hour postprandial glucose levels were highly correlated and thus not counted as two independent phenotypes here. In the secondary analyses, the significance level was further corrected for the two investigated subgroups yielding a significance level of 0.008 (0.05/6). More detailed information on statistical procedures is given in the online appendix.
Analysis in incident T2DM patients
In an additional exploratory analysis, we combined the linear regression estimates of baseline data from the incident T2DM cases of the two cohort studies to obtain estimates of the IL6 -174G C association with BMI and IL-6 levels (glucose not available) among future T2DM subjects before they became cases ('prediabetic subjects').
Results

Study recruitment
Seventeen studies with 25,635 participants met the study and subject inclusion criteria and were included in the joint analyses (see Table I for an overview). Online appendix Table A-III shows for which outcome the respective study qualified for analysis; online appendix Table A-IV presents the number of participants per study included in the analyses of the respective quantitative trait. All 17 studies with 25,635 subjects were analyzed for the outcome BMI. Association analyses with BMI as main outcome had been unpublished in 12 studies at the time of study recruitment (called 'unpublished for BMI' in the following). Eight studies with 10,725 participants were analyzed for fasting glucose, seven of them unpublished for this trait; seven studies with 8399 participants were analyzed for 2-hour glucose (all unpublished). For the outcome circulating IL-6 levels, data from seven studies with 5659 participants were analyzed, six of them unpublished for IL-6 levels.
Study-specific statistics
Detailed characteristics of included studies and participants are summarized in online appendix Table A-V. All studies had been conducted in European populations. Genotype frequencies of non-diabetic subjects were in HWE for all studies, except for the BOTNIA and the TGN study, which were thus excluded from the main analyses. This left 9440, 7398, 24,117, and 5659 subjects for the analysis of fasting glucose, 2-hour glucose, BMI, and circulating IL-6, respectively (see online appendix Table A-IV). The IL6 -174 C-allele frequency of non-diabetic subjects with genotype frequencies in HWE ranged from 41.1% (95% CI 038.3Á43.8) in the KORA-MIFAM study to 55.0% (95% CI 0 51.4Á58.6) in the FUSION 1 study.
IL6 -174G C and circulating glucose
The outcome fasting glucose was investigated as full data main analysis for the seven studies where the genotype frequencies of non-diabetic subjects were in HWE, including 9440 subjects. Figure 1 shows the study-specific and the summary b-coefficients, using a dominant model for the C-allele. Most studies exhibited a reduction of fasting glucose levels, though not significant in each study separately. The summary estimate provided a statistically significant decrease of (0.091 mmol/L (95% CI 0((0.163)Á((0.018), P 00.014), corresponding to a decrease of about 1.5% for subjects with GC-or CC-genotypes compared to GG. T2DM status-specific analyses showed a more pronounced reduction of (0.317 mmol/L (95% CI 0((0.584)Á((0.049), P 00.020) among T2DM subjects. Table II provides model-free summary estimates, indicating that the dominant genetic model was consistent with the data.
The full data main analysis of 2-hour glucose included six studies with 7398 subjects. There was no statistically significant association between IL6 -174G C and 2-hour glucose (C-allele dominant model for full data analysis: b 0(0.075 mmol/L, 95% CI 0((0.201)Á(0.051), P00.243) (Table II) .
IL6 -174G C and body mass index
The full data main analysis of the outcome BMI included 15 studies with 24,117 subjects. (mmol/L) Figure 1 . Forest plot, illustrating the study-specific b-coefficients with 95% CIs for the association between IL6 -174GC, dominant model for the C-allele, and fasting glucose in (A) the full data analysis (combined group of non-diabetic and prevalent type 2 diabetes mellitus (T2DM) subjects), (B) only in non-diabetic subjects, and (C) only in prevalent T2DM subjects, adjusted for age, sex, and body mass index (BMI). Additionally, the summary fixed-effect ß-coefficient is shown. I 2 measures the impact of inconsistency across studies and can range between 0% and 100%.
shows the study-specific and the summary b-coefficients applying the dominant model for the C-allele. There was no statistically significant evidence for an association between IL6 -174G C and BMI in the full data (b00.088, 95% CI 0((0.023)Á(0.200), P 00.120) or the T2DM status-specific analyses (P 0.10) (Table II) .
IL6 -174G C and circulating interleukin-6 levels
There was no evidence in the full data joint analysis including 5659 subjects of seven studies for an association between IL6 -174G C and circulating IL-6 levels (Table II and Figure 3 ). Likewise, there was no statistically significant IL-6 level association among the 4621 non-diabetic subjects of six studies or among the 966 prevalent T2DM subjects of four studies.
Analysis of BMI and IL-6 levels in incident T2DM cases before they became cases Among the 641 incident T2DM subjects before they became type 2 diabetic, there was no association with BMI (P 0.10). Regarding circulating IL-6, the IL6 -174G C showed no association in the dominant model, but higher levels for the homozygous CC-genotype (b CCvsGG 00.266, 95% CI 00.085Á 0.448, P00.004) compared to the GG-genotype.
Sensitivity analyses
Regarding fasting glucose, 2-hour glucose, or IL-6 levels, there was no evidence for publication bias: the Egger's regression test was non-significant (P 0.10), and excluding published studies would not change the main findings (online appendix Table A-VI). Regarding BMI, there was some evidence for publication bias. In the five published studies with 10,704 subjects, the IL6 -174 C-allele was statistically significantly associated with higher BMI (b 0 0.190, 95% CI 00.023Á0.358). In contrast, there was no association in the ten unpublished studies with 13,413 subjects (b 00.007, 95% CI 0 ((0.142)Á(0.157)). Moreover, the funnel plot (online appendix Figure A-1 ) and the Egger's regression test (P 00.06) showed some evidence for publication bias of the summary BMI estimate when including all 15 studies, but none when restricting to the ten unpublished studies (P 00.27).
Including studies with genotype HWE violation (online appendix Table A-VII) or omitting adjustment for BMI or T2DM status (data not shown) would not change our main findings. Furthermore, there were no large differences between association Table II . Summary results of association between IL6 -174GC and fasting glucose, 2-h glucose, body mass index (BMI), or interleukin-6 (IL-6) levels. The fixed-effect results are presented for the full data analysis a and for analyses stratified for type 2 diabetes status (T2DM).
Full data analysis a Non-diabetic subjects Type 2 diabetic subjects Analysis of non-diabetic and prevalent T2DM subjects together. The sum of the number of non-diabetic and T2DM subjects in stratified analyses does not yield the number of subjects in the full data analysis, because stratified analyses were performed in individual studies only if there were at least 50 non-diabetic or T2DM subjects available.
b Summary estimates from generalized linear models adjusted for age and sex (for BMI and IL-6 levels: additionally adjusted for T2DM status; for glucose and IL-6 levels: additionally adjusted for BMI Figure 2 . Forest plot, illustrating the study-specific ß-coefficients with 95% CIs for the association between IL6 -174GC, dominant model for the C-allele, and body mass index (BMI) of (A) the full data analysis, (B) only non-diabetic subjects, and (C) only prevalent type 2 diabetes mellitus (T2DM) subjects, adjusted for age, sex, and T2DM status (A). Please refer to Figure 1 legend for more details. estimates of men and women in sex-stratified analyses (data not shown). Sensitivity analyses using ln-transformed fasting glucose levels, ln-transformed BMI levels, or age-and sex-preadjusted standard z-scores (all outcomes) to obtain phenotype distributions which are closer to normal yielded results which were very similar to the main analyses. Likewise, exclusion of outliers (fasting glucose B2.78 or 20.00 mmol/L, full data analysis: n 047; BMI B16.0 or 50.0 kg/m 2 , full data analysis: n028; IL-6 levels B0.20 or 20.0 pg/mL, full data analysis: n 0250, prevalent T2DM subjects: n 030) did not change the main results, except for a stronger association between IL-6 levels (natural logarithm) and the IL6 -174 CC-versus GG-genotype (b 00.226, 95% CI: 0.098Á0.355, P 00.0006). Pooling the individual data rather than using a metaanalysis approach yielded very similar results for all analyses. Interestingly, a subgroup analysis with exclusion of the two studies (DANISH and RMI-FAM) with self-reported BMI data increased the BMI association estimate (C-allele dominant model: b 00.172 kg/m 2 , 95% CI: 0.033Á0.312, P 00.015).
Discussion
Major findings
In this joint analysis of individual-level data from 9440 study participants, C-allele carriers of the IL6 -174G C polymorphism had lower fasting glucose levels ((0.091 mmol/L, P00.014) independently of BMI. No association was found with BMI in 24,117 subjects or with IL-6 levels in 5659 subjects. The estimates were robust against exclusion of outliers, various transformations of variables including use of Summary Association Estimate β β ln of (pg/mL) Figure 3 . Forest plot, illustrating the study-specific ß-coefficients with 95% CIs for the association between IL6 -174 CC versus GG and natural logarithm of circulating interleukin-6 (IL-6) levels of (A) the full data analysis, (B) only non-diabetic subjects, and (C) only prevalent type 2 diabetes mellitus (T2DM) subjects, adjusted for age, sex, body mass index (BMI), and T2DM status (A). Please refer to Figure 1 legend for more details.
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standardized z-scores, or when applying different meta-analysis methodology.
IL6 -174G C and circulating glucose
The present analysis results of the IL6 -174G C with fasting glucose was in line with our previous joint analysis on T2DM, which had shown that individuals carrying the IL6 -174 C-allele had 9% lower odds for T2DM compared to individuals with the GG-genotype (P 00.037) (25) . We also confirmed the dominant genetic model. Our previous T2DM analysis had included a larger number of subjects; when restricting to the seven studies with fasting glucose data, a T2DM summary odds ratio (OR) of 0.89 (95% CI 00.78Á1.02) with a nonsignificant P-value of 0.09 would have been yielded, which impressively demonstrates the gain from additional information by using glucose as a quantitative variable. The recent finding of an association between the IL6 -174 C-allele and T2DM (OR C-allele dominant model00.75 (95% CI 00.57Á0.98)) in the French D.E.S.I.R. study including 307 T2DM cases and 2919 normoglycemic controls (29) adds strength to our hypothesis that IL6 -174G C truly has an impact on individual T2DM risk.
IL6 -174G C and body mass index
Several lines of evidence suggest that the cytokine IL-6 plays a role in the regulation of body composition, probably by acting in a catabolic manner (30Á 32). To date, association between IL6 -174G C and obesity has been investigated by several comparably small studies with inconsistent results (17, 18, 20, 21, 33) . Qi et al. recently conducted a large meta-analysis of mainly published studies including 26,944 subjects and found statistically significant heterogeneity between study-specific association estimates. Applying a random effects model in consequence, there was no evidence for an association between IL6 -174G C and BMI (34) . Our joint analysis of 24,117 subjects also did not find an association between IL6 -174G C and BMI and added to the previous meta-analysis by sole inclusion of individual-level data which enabled application of completely standardized analysis methods resulting in low between-study heterogeneity and by inclusion of mostly unpublished studies (56% of the analyzed study participants). There was only a small study overlap of 6631 subjects (27%) between the present joint analysis and the Qi et al. meta-analysis. Our power to detect a BMI difference of 0.2 kg/m 2 or 0.3 kg/m 2 between IL6 -174 C-allele carriers and non-carriers was more than 80% or nearly 100%, respectively, given the type 1 error probability of 0.050/3 00.017, a GG-genotype frequency of 31.2%, and a BMI standard deviation of 4.2 kg/m 2 .
IL6 -174G C and circulating interleukin-6 levels
The current literature on the association between the IL6 -174G C and circulating IL-6 levels is inconclusive. Several studies, with the largest including 641Á1526 Caucasians (23,24,35Á37), did not find evidence for association. However, other studies with the largest being the recently published Cardiovascular Health Study (CHS) with 4714 elderly Caucasians (72 years median age) and a high prevalence of T2DM (28%) showed borderline significantly higher IL-6 levels for CC-genotype subjects compared to GG (P00.04) (38) . In our joint analysis of 5659 Caucasians there was no evidence for association between IL6 -174G C and circulating IL-6 levels including non-diabetic and manifest T2DM subjects. Reasons for our nonfinding of an effect as compared to the CHS study might be a smaller power in a joint analysis compared to a single study, an effect only present in special risk groups, or a true non-existence of the effect. Our exploratory analysis of increased IL-6 levels with the CC-genotype in the 641 incident T2DM subjects would be in line with the CHS study. In summary, our joint analysis was not able to resolve the puzzle whether and how IL-6 levels mediate the association between IL6 -174G C and T2DM by pin-pointing a direct association between the polymorphism and IL-6 levels. Thus, even larger studies optimally with a prospective design might be warranted.
Strengths and limitations of this joint analysis
The large number of subjects analyzed in our investigation was a definite strength. For all analyzed phenotypes, our study represents the largest study on individual-level data conducted to date to address the role of IL6 -174G C. Thus, we were able to reveal small associations, which nevertheless are of importance due to the high prevalence of the genetic variant in the general population (41%Á55%) and their potential to help understand the pathogenesis of this severe disease. Our non-finding of an association with BMI in this highly powered study may also be of great importance to solve to some extent the puzzle from contrary reports.
Furthermore, it was a distinctive strength of our joint analysis that it was based on individual participants' data allowing for standardized data cleaning and analysis, to which the low heterogeneity among study-specific estimates may be attributed.
Finally, our analysis included many unpublished studies, which guards against the greatest threats of meta-analyses, the publication or selective reporting bias. Stratifying for published or unpublished studies depicted a potential of some bias for the published association studies of IL6 -174G C and BMI.
It may be considered a limitation that all T2DM status-specific analyses exhibited truncated glucose distributions, which consequently also affected the correlated BMI and IL-6 level distributions. In addition, no data were available on antidiabetic medication for T2DM subjects for the glucose analyses or on physical activity before blood extraction for the circulating IL-6 level analyses. This might have decreased the precision of the estimates but is unlikely to have caused false-positive findings.
Conclusion
This joint analysis represents by far the largest individual participants' data analysis to date on the association of the IL6 promoter polymorphism -174G C with quantitative phenotypes relevant for T2DM. Our data indicate that C-allele carriers of the widely debated IL6 -174G C polymorphism have lower fasting glucose levels on average, which substantiates previous findings of decreased T2DM risk of these subjects. Therefore, our study suggests IL6 as a T2DM gene. No statistically significant association was found for quantitative BMI or IL-6 concentrations. In general, we demonstrated that a consortium-based approach involving individual participants' data and standardized analysis is well suited to investigate genetic variants with small effects.
Body mass index was calculated as weight (kg) divided by squared height (m 2 ) from measured anthropometric data, except for the RMIFAM and DANISH studies where self-reported data were used. An overview on methods used to quantify circulating interleukin-6 (IL-6) levels is presented in Table A-I. A questionnaire was sent to all principal investigators to collect data on genotyping methods and quality. This information is also summarized in Table A-I. As IL6 -174G C is a G/C-polymorphism, and allele G is complementary to allele C, the genotyping sequences and strands, assessed via the questionnaire, were compared with a reference to confirm that the allele labeling was performed consistently across all studies.
Further details on the statistical analyses
Statistical analyses were performed using SAS software version 9.1 (Cary, NC, USA). IL6 -174G C allele and genotype frequencies were estimated, accounting for the correlation in family data by use of an exchangeable structure in a generalized estimating equations approach (SAS PROC GEN-MOD). Hardy-Weinberg equilibrium (HWE) was tested in non-diabetic subjects (SAS PROC AL-LELE); for family studies only one randomly drawn subject per family was included. In order to approximate a normal distribution, circulating IL-6 was logarithmically transformed.
Publication bias was investigated by visual inspection of funnel plots and by the Egger's regression test (3). Funnel and forest plots were prepared using Review Manager software version 4.2 (Cochrane Collaboration, Copenhagen, DK).
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For personal use only. Successfully genotyped individuals in percent of all subjects intended for genotyping. n.a.0not applicable; NIDDM0non-insulin-dependent diabetes mellitus; MI0myocardial infarction.
For personal use only. The Botnia Study began in 1990 as a family-based study aiming to identify genes increasing susceptibility to T2DM. Type 2 diabetic subjects from the area of five health care centers in the Botnia region of Western Finland were invited to participate together with their family members. For the purpose of this joint analysis, unrelated individuals were genotyped for IL6 -174G C. According to a priori defined criteria, one type 2 diabetic individual per family was selected. Non-diabetic subjects comprise cases' spouses and unrelated individuals, all being 35 years or older.
Captopril Prevention Project (CAPPP) CAPPP is a prospective randomized clinical trial conducted in Sweden and Finland during the 1990s. Patients aged 25Á66 years, with a measured diastolic blood pressure of 100 mmHg or more on two occasions, were recruited at health centers and randomly assigned to captopril or conventional antihypertensive treatment. Exclusion criteria were secondary hypertension, serum creatinine concentration of more than 150 mmol/L, and disorders that required treatment with ß-blockers. Cases had T2DM at base-line or were diagnosed during the follow-up. This joint analysis includes a substudy of the Swedish part of CAPPP, which has been genotyped for IL6 -174GC. This substudy comprises all patients that got myocardial infarction (MI), plus two control subjects without MI per patient, matched with respect to gender, age, and smoking. Further details: (4).
Danish Study
The DANISH case-control study of T2DM involves all 4568 subjects with normal glucose tolerance (NGT) from the Inter99 cohort and 1389 unrelated type 2 diabetic patients recruited from the outpatient clinic at Steno Diabetes Center, Copenhagen and the Research Center for Prevention and Health through the Inter99 study. The Inter99 cohort is a population-based randomized non-pharmacological intervention study for prevention of cardiovascular disease done at the Research Center for Prevention and Health involving 6514 Caucasian subjects (6164 with data from an oral glucose tolerance test). Further details: (5).
Ealing Diabetes Study of Coagulation (EDSC)
The type 2 diabetic individuals of the EDSC study were recruited consecutively from the Ealing Hospital diabetes clinic in London, UK. Patients completed a questionnaire with details of age, ethnicity, smoking habit, fasting status, duration of diabetes, and other clinical details. Blood was collected for plasma and DNA analysis. Several further parameters, such as BMI, were measured. Type 2 diabetic individuals (n0927) comprised primarily three ethnic groups: Indian Asian, n0503; UK white, n0 331; black Afro-Caribbean, n 093. Further details: (6) . To ensure comparability with the other Caucasian studies, only the white subjects were included in this joint analysis.
European Prospective Investigation into Cancer and Nutrition Potsdam (EPIC-Potsdam)
A nested case-control study was designed within the European Prospective Investigation into Cancer and Nutrition Potsdam cohort (EPIC-POTSDAM_nCC-T2DM), which is part of the European multicenter, population-based EPIC-study including 27,548 subjects from the area around Potsdam, Germany (women aged 35Á65 years and men aged 40Á65 years). Base-line examination and blood sampling were conducted between 1994 and 1998. Data presented in this joint analysis are based on the first follow-up questionnaires sent to the study participants on average 2.3 years after base-line examination. Further details: (7) . To ensure comparability with the other cross-sectional studies, only the non-diabetic control subjects were included in this joint analysis. Cases were free of T2DM at base-line and developed their incident T2DM during the follow-up. Analyses of their data are presented separately. Ann Med Downloaded from informahealthcare.com by University of Michigan Health System For personal use only. 
Girona Genetics of Diabetes Study
The type 2 diabetic patients of the Girona Genetics of Diabetes Study were consecutively recruited subjects from the diabetes clinics at the Hospital of Girona, Spain. The non-diabetic subjects are unrelated healthy Caucasian middle-aged subjects recruited from the general population. Further details: (2) .
KORA Studies in chronological order KORA (Cooperative Health Research in the Region Augsburg) is a regional research platform in the German city of Augsburg and the two adjacent counties, for population-based studies, subsequent follow-up studies, and family studies in the fields of epidemiology, health economics, and health care research. KORA was established in 1996 to expand the WHO (World Health Organization) MONICA (Monitoring of Trends and Determinants in Cardiovascular Disease) project in Augsburg. In the framework of MONICA, three independent cross-sectional population-representative surveys were conducted in 1984/85 (S1), 1989/90 (S2), and 1994/95 (S3), and a population-based acute myocardial infarction registry was set up. The study subjects of all Augsburg MONICA and KORA surveys and the family studies on myocardial infarction and T2DM are of German nationality and were studied by physical examination, blood testing, and a standardized interview in KORA study centers. All tests were carried out by specially trained personnel. Further details: (10Á12). Some individuals were originally recruited for two or more studies, but were assigned to one of the included KORA studies for the purpose of this joint analysis according to a priori defined criteria.
MONICA/KORA Survey S3 The MONICA/KORA Survey S3 originally investigated 4856 individuals. Study participants that are included in the MONICA/ KORA Case Cohort Study S123 were eliminated from subjects of the MONICA/KORA Survey S3 for this joint analysis.
KORA MI Family Study
Patients with MI prior to the age of 60 years and their siblings were identified through the acute myocardial infarction registry. The diagnosis of MI was established according to the MONICA diagnostic criteria. Of 1254 patients contacted, 609 agreed to participate in the study (532 men, aged 56.190.3 years). Moreover, 540 siblings without MI (251 men, aged 54.690.4 years from 325 families) were recruited and examined by the same protocol.
KORA Survey S4 (KORA S4) The KORA S4 studied a population-representative sample of 4261 subjects, 25Á74 years old, during the years 1999Á2001. The sample design followed the guidelines of the three previous MONICA Augsburg surveys. In the age-range of 55Á74 years, 1653 persons participated in an OGTT. These participants were genotyped for IL6 -174GC and included in this joint analysis. Further details: (13) . Ann Med Downloaded from informahealthcare.com by University of Michigan Health System For personal use only. Families were ascertained through an index proband with known T2DM, who had at least one full sib or both parents willing to participate in the study. All available members of the index probands' nuclear families, i.e. full sibs and parents, were included. Index probands were all from the city or region of Augsburg. They were recruited from T2DM patients of the Central Hospital of Augsburg, from earlier MONICA and KORA studies, from the acute myocardial infarction registry, or via public relations. All participants were living in Germany, and all were of European origin. Most subjects were extensively phenotyped in the KORA study center, some were examined by their family doctor, who decided whether or not the subject had T2DM and took blood samples for DNA analyses. Data of the sibling generation was included in this joint analysis.
MONICA/KORA Case Cohort Study S123 All participants of at least one of the three MONICA Augsburg surveys were prospectively followed for the MONICA/KORA Case Cohort Study S123. The study was restricted to participants aged 35Á74 years at base-line, since the incidence of T2DM is low in younger subjects. A stratified random sample of the source population, containing 1885 subjects, was selected. A total of 555 incident cases of T2DM were observed between participants' study start dates and 31st December 2002. Further details: (14) . For the purposes of this joint analysis on quantitative phenotypes, the base-line data of the MONICA/KORA Case Cohort Study S123 (prevalent T2DM and non-diabetic subjects) without the participants who developed their incident T2DM during the follow-up were used to ensure comparability with the other cross-sectional studies (MONICA/KORA-BASE). Analyses of the subjects with incident T2DM are presented separately.
Regensburg MI Family Study
The kindreds of the Regensburg MI Family Study were ascertained through MI index patients, who were identified by screening 93,500 patient charts in seven cardiac in-hospital rehabilitation centers distributed throughout Germany. Index patients had all suffered from MI before 60 years. If at least one sibling had suffered from MI or had severe coronary artery disease or by-pass surgery, the index patient with all available parents and siblings were contacted and invited to participate in the study. All participating individuals filled out a standardized questionnaire that focused on cardiovascular risk factors, medical diagnoses, lifestyle and medication. Further details: (15) . Data of the sibling generation were included in this joint analysis.
Second Northwick Park Heart Study (NPHS II) For the NPHS II Study, 3012 unrelated healthy Caucasian middle-aged male subjects were recruited from nine general medical practices scattered throughout the UK and prospectively followed from 1989. Sixty-eight subjects with diabetes at base-line were excluded from analysis. Further details: (16) .
Tarraco Study For the Tarraco study, 211 unrelated type 2 diabetic subjects were recruited from the outpatient clinic at Hospital Universitari de Tarragona 'Joan XXIII' during the years 2000Á2004. Simultaneously, 118 healthy subjects were recruited from the same hospital. The numbers of participants presented for the original studies do not always match the numbers used in the analyses of this joint analysis. The reason is that some subjects of the original studies were not included in the joint analysis because of study overlap, missing genotype data, or missing phenotype data. Ann Med Downloaded from informahealthcare.com by University of Michigan Health System
